Keensight Capital

About Keensight Capital

Keensight Capital is a European growth equity firm with €8.0 billion of assets under management as of December 2024, headquartered in Paris with additional offices in London and Boston. The firm specialises in growth equity investments in profitable technology and healthcare companies, with a 25-year track record across multiple flagship Keensight Nova vintage funds. Keensight focuses exclusively on profitable scaling businesses rather than early-stage venture, distinguishing the platform from traditional VC and pure buyout firms.

Investment thesis

Keensight targets European growth equity in profitable technology and healthcare companies with €30 million-plus annual revenue and proven business models, deploying significant minority and selective majority equity positions through equity tickets ranging from €20 million to €200 million per transaction. Sector focus spans Software (vertical SaaS, enterprise software, fintech), HealthTech (medical software, digital health, life sciences tools) and selective Industrial Technology positions. The growth-equity-only mandate enables Keensight to support founders and management teams through scale-up phases without operational disruption of full LBO structures.

Recent activity

Recent realised exits include 3PBIOVIAN (TMT, 2024), GEODESIAL group (healthcare, 2024), Menix (healthcare, 2024), Vision-Box (TMT, 2024), A2Mac1 (TMT, 2023) and I-Tracing (TMT, 2023), reflecting strong distribution across the technology and healthcare franchises. The platform tracks 3 funds, 34 active portfolio companies and 23 realised exits, with continued deployment from the latest Nova vintage across European growth equity opportunities. Detailed buyer names and multiple data available on Pro at €29/month.